U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
17 déc. 2021 14h05 HE
|
Global Blood Therapeutics, Inc.
New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE)...
GBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior Notes
15 déc. 2021 01h04 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its...
GBT Announces Proposed Offering of $250.0 Million of Convertible Senior Notes
14 déc. 2021 07h28 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount...
GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
13 déc. 2021 09h00 HE
|
Global Blood Therapeutics, Inc.
GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies...
GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition
12 déc. 2021 09h00 HE
|
Global Blood Therapeutics, Inc.
Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with Oxbryta ...
GBT Announces New Employment Inducement Grants
09 déc. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2021, the compensation committee of GBT’s board...
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program
02 déc. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.; The ASH Research Collaborative
WASHINGTON and SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of...
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
24 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th...
GBT Announces Participation in Upcoming Investor Conferences
12 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel...
GBT Announces New Employment Inducement Grants
08 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on November 1, 2021, the compensation committee of GBT’s board...